Donated Blood Could Be Transformed Into Universal Type
By LabMedica International staff writers Posted on 10 May 2015 |
Image: Hemagglutination test of red cells used for typing ABO blood groups (Photo courtesy of University College London).
Blood transfusions are critically important in many medical procedures, but the presence of antigens on erythrocytes means that careful blood-typing must be carried out prior to transfusion to avoid adverse and sometimes fatal reactions following transfusion.
Every day, thousands of people need donated blood, but only blood without A- or B-type antigens, such as type O, can be given to all of those in need, and it's usually in short supply. However an efficient way to transform A and B blood into a neutral type that can be given to any patient has been reported.
Scientists at the University of British Columbia (Vancouver, BC, Canada) working with other Canadian and French investigators studied how to enzymatically remove the terminal N-acetylgalactosamine or galactose of A- or B-antigens, respectively, which would yield universal O-type blood. They started with the family 98 glycoside hydrolase from Streptococcus pneumoniae SP3-BS71 which cleaves the entire terminal trisaccharide antigenic determinants of both A- and B-antigens from some of the linkages on red blood cell surface glycans. Through several rounds of evolution, they developed variants with vastly improved activity toward some of the linkages that are resistant to cleavage by the wild-type enzyme.
The investigators fine-tuned one of those enzymes and improved its ability to remove type-determining sugars by 170-fold, rendering it antigen-neutral and more likely to be accepted by patients regardless of their blood type. The authors concluded that the resulting enzyme effects more complete removal of blood group antigens from cell surfaces, demonstrating the potential for engineering enzymes to generate antigen-null blood from donors of various types. In addition to blood transfusions, the scientists say their advance could potentially allow organ and tissue transplants from donors that would otherwise be mismatched. The study was published on April 14, 2015, in the Journal of the American Chemical Society.
Related Links:
University of British Columbia
Every day, thousands of people need donated blood, but only blood without A- or B-type antigens, such as type O, can be given to all of those in need, and it's usually in short supply. However an efficient way to transform A and B blood into a neutral type that can be given to any patient has been reported.
Scientists at the University of British Columbia (Vancouver, BC, Canada) working with other Canadian and French investigators studied how to enzymatically remove the terminal N-acetylgalactosamine or galactose of A- or B-antigens, respectively, which would yield universal O-type blood. They started with the family 98 glycoside hydrolase from Streptococcus pneumoniae SP3-BS71 which cleaves the entire terminal trisaccharide antigenic determinants of both A- and B-antigens from some of the linkages on red blood cell surface glycans. Through several rounds of evolution, they developed variants with vastly improved activity toward some of the linkages that are resistant to cleavage by the wild-type enzyme.
The investigators fine-tuned one of those enzymes and improved its ability to remove type-determining sugars by 170-fold, rendering it antigen-neutral and more likely to be accepted by patients regardless of their blood type. The authors concluded that the resulting enzyme effects more complete removal of blood group antigens from cell surfaces, demonstrating the potential for engineering enzymes to generate antigen-null blood from donors of various types. In addition to blood transfusions, the scientists say their advance could potentially allow organ and tissue transplants from donors that would otherwise be mismatched. The study was published on April 14, 2015, in the Journal of the American Chemical Society.
Related Links:
University of British Columbia
Latest Hematology News
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
- First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
- POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
- First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
- Handheld White Blood Cell Tracker to Enable Rapid Testing For Infections
- Smart Palm-size Optofluidic Hematology Analyzer Enables POCT of Patients’ Blood Cells
- Automated Hematology Platform Offers High Throughput Analytical Performance
- New Tool Analyzes Blood Platelets Faster, Easily and Accurately
- First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC
- Bleeding Risk Diagnostic Test to Reduce Preventable Complications in Hospitals
- True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Point of Care CBC Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput
- Blood Test Could Predict Outcomes in Emergency Department and Hospital Admissions
- Novel Technology Diagnoses Immunothrombosis Using Breath Gas Analysis
- Advanced Hematology System Allows Labs to Process Up To 119 Complete Blood Count Results per Hour
- Unique AI-Based Approach Automates Clinical Analysis of Blood Data